De Quervain's Tenosynovitis
Investigational use for stenosing tenosynovitis of the first dorsal extensor compartment; small case series.
Resumen para el Paciente
- ¿Está esto autorizado por FDA para este uso?
- Not FDA-cleared for de Quervain tenosynovitis. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is investigational.
- ¿Qué evidencia existe?
- Tier C (investigational). There are no published controlled trials. Evidence-based care: thumb spica splinting (the strongest non-operative evidence), NSAIDs, activity modification (avoiding repetitive thumb abduction and ulnar deviation), local corticosteroid injection (the highest-evidence single intervention - cure rate around 80 percent), and (refractory) surgical release of the first dorsal compartment. New onset in postpartum women (mommy thumb) usually responds well to splinting and corticosteroid injection.
- Riesgos principales
- Bleeding from each bite site for 6 to 24 hours after detachment
- Bruising over the radial wrist for 5 to 10 days
- Local skin or, rarely, Aeromonas hydrophila infection
- Allergic reaction to leech saliva (uncommon)
- RISK if leech is placed over the radial artery or radial sensory nerve
- Worsening tendon pain from local irritation
- Delay of thumb spica splinting and corticosteroid injection - which have the strongest evidence
- Quién no debería considerar esto
- Patients who have not tried thumb spica splinting for at least 4 to 6 weeks
- Patients who have not tried corticosteroid injection (the highest-evidence single intervention)
- Patients with intersection syndrome, CMC arthritis, or radial sensory neuritis mimicking de Quervain
- Patients on anticoagulants, with hemophilia, or with severe anemia
- Patients with active dermatitis or broken skin over the radial wrist
- Patients with peripheral vascular disease affecting the wrist
- Qué preguntar a su clínico
- Have we confirmed de Quervain tenosynovitis with Finkelstein or Eichhoff testing?
- Have we ruled out intersection syndrome, CMC arthritis, and radial sensory neuritis?
- Have I tried a thumb spica splint for at least 4 to 6 weeks?
- Have I tried corticosteroid injection - the highest-evidence single intervention?
- Am I a candidate for surgical release of the first dorsal compartment if conservative care fails?
- Where exactly will the leech be placed - confirm placement avoids the radial artery and radial sensory nerve?
- What is the Aeromonas-prevention protocol?
- Cuándo buscar atención urgente
- Sudden severe pain with inability to grip or move the thumb (possible tendon rupture)
- Numbness, tingling, or hypersensitivity on the dorsal radial hand (possible radial sensory neuritis)
- Acute swelling, severe pain, or cold pallor of the hand or wrist
- Bleeding from a bite site lasting more than 24 hours
- Fever, chills, or spreading redness at the bite site
- Hives, facial or throat swelling, or breathing difficulty
Qué NO significa esto
- This is not FDA-cleared for de Quervain tenosynovitis.
- No controlled trials support efficacy.
- It does not replace thumb spica splinting and corticosteroid injection - which together have an excellent cure rate.
- It does not address intersection syndrome, CMC arthritis, or radial sensory neuritis - which need different management.
- Placement near the radial artery and superficial radial nerve carries vascular and nerve-injury risk if practitioner is not skilled.
Referencias cruzadas de seguridad
Clinical Profile
- Category
- musculoskeletal
- ICD-10
- M65.4
- Safety tier
- low
Evidence Summary
De Quervain's tenosynovitis affects the APL and EPB tendons within the first dorsal extensor compartment. Conventional management includes thumb spica splinting, NSAIDs, and corticosteroid injection, which has a high response rate. No controlled clinical trial or case series of leech therapy for de Quervain's tenosynovitis has been published; use is investigational and mechanistic only. Corticosteroid injection remains the standard second-line therapy, and surgical release is reserved for refractory cases.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Ranjan A et al. (2020), n=18
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Recent local corticosteroid injection (<4 weeks)
- Active local infection
Related Conditions
Knee Osteoarthritis
Off-label use with three RCTs showing pain and function improvement comparable to NSAID gel at 3 months in mild-to-moderate symptomatic knee OA.
Thumb Carpometacarpal (CMC-1) Osteoarthritis
Off-label use with RCT evidence: single-session leech therapy reduces pain and improves function in CMC-1 (basal thumb) OA at 8 weeks.
Lateral Epicondylitis (Tennis Elbow)
Off-label use with two RCTs showing significant pain reduction at 7-12 weeks compared to topical NSAID and conventional physiotherapy.
Plantar Fasciitis
Off-label use with one RCT showing significant heel pain reduction at 6 weeks compared to conservative care.